SCHEMBL4102322

SCHEMBL4102322

CCC(=O)c1cccc2c(Cl)cccc12

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.48
CYP2A6 P11509 1/20 0.48
KMT2A Q03164 3/20 0.46
ATM Q13315 1/20 0.46
POLB P06746 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.42
TAS1R3 Q7RTX0 1/20 0.41
TAS1R1 Q7RTX1 1/20 0.41
TAS1R2 Q8TE23 1/20 0.41
TSHR P16473 2/20 0.41
ERCC5 P28715 2/20 0.41
FEN1 P39748 2/20 0.41
CES2 O00748 1/20 0.41
CES1 P23141 1/20 0.41
PTPN1 P18031 1/20 0.41
CNR1 P21554 2/20 0.40
CNR2 P34972 2/20 0.40
MEN1 O00255 1/20 0.40
ESRRA P11474 1/20 0.40
LMNA P02545 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4098841 0.89 KMT2A (0.59) CYP1A2CYP2A6KMT2AATMPOLB
SCHEMBL4104928 0.87 CYP1A2 (0.46) CYP1A2CYP2A6KMT2AATMPOLB
SCHEMBL4109098 0.83 KCNH2 (0.39) CYP1A2KMT2APOLBL3MBTL1TSHR
SCHEMBL4109492 0.82 POLB (0.41) CYP1A2KMT2AATMPOLBL3MBTL1
SCHEMBL4104266 0.81 PTPN1 (0.62) CYP1A2CYP2A6KMT2AATMPOLB
SCHEMBL2255346 0.81 ERCC5 (0.61) KMT2ATAS1R3TAS1R1TAS1R2TSHR
SCHEMBL2837238 0.80 ERCC5 (0.58) CYP1A2KMT2APOLBERCC5FEN1
SCHEMBL4099076 0.79 CYP1A2 (0.50) CYP1A2CYP2A6KMT2APOLBL3MBTL1
SCHEMBL11057939 0.79 HSP90AB1 (0.47) CYP1A2KMT2APOLBL3MBTL1TSHR
SCHEMBL1262256 0.79 KLKB1 (0.47) KMT2ATAS1R3TAS1R1TAS1R2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090221645-A1 Dihydroimidazothiazole Derivatives PROSIDION LIMITED (GB) 2009-09-03 US disclosed
US-20090221645-A1 Dihydroimidazothiazole Derivatives PROSIDION LIMITED (GB) 2009-09-03 US disclosed
US-20090221645-A1 Dihydroimidazothiazole Derivatives PROSIDION LIMITED (GB) 2009-09-03 US disclosed
CN-101155817-A Dihydroimidazothiazole derivatives PROSIDION LTD (GB) 2008-04-02 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090221645-A1 Dihydroimidazothiazole Derivatives TPH1, HTR3B, HTR1A CYP1A2 137/4885CYP2A6 447/4885KMT2A 2634/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.